title: Effects of human tumor cell lines on local new bone formation in vivo.
abstract: Although some tumors cause osteolytic lesions, there are some that stimulate new bone formation. This is an important phenomenon because the responsible mechanisms probably represent an aberration of normal physiological bone formation, and identifying the factors involved in the process may lead to new therapies for various bone diseases. To clarify our understanding of the potential mechanism responsible, we compared and quantitated the extent of new bone formation stimulated by human tumors (HeLa, Hep-2, AV-3, FL, WISH and KB), some of which have osteogenic activity in vivo [2]. Tumor cells were injected over the calvaria of nude mice to examine formation of new bone. The tumor cells produced three histologically distinct patterns of new bone growth: (1) WISH and KB stimulated appositional bone growth adjacent to periosteal bone surfaces; (2) HeLa and Hep2 induced new bone growth over calvarial surface even when distant from the tumor mass; (3) FL stimulated bone formation adjacent to periosteum as well as ectopic bone formation in sites distant from bone. All tumors except AV3 induced mean new bone thickness >100 microm, and Hep-2 cells produced bone 330 microm thick. PCR and Northern blot analysis of mRNA isolated from cultured tumor cells revealed that all cell lines expressed mRNA for TGFbeta, (fibroblast growth factor) FGF-1, FGF-2, and IGF-I, and most cell lines produced mRNA for PDGF. Only FL expressed large amounts of mRNA for BMP2. In serum-free conditioned media from Hep2 and HeLa cells purified by heparin affinity chromatography, we have identified FGF-I, FGF-2, and PDGF by immunodetection with specific antibodies. Our results show that new bone growth caused by these tumors is likely due to the production of bone growth factors by the tumor cells, and that the overall effects on bone may be due to several factors working in concert.
authors.affiliation: OsteoSA, Inc., San Antonio, Texas 78229, USA.
authors.forename: E
authors.initials: E
authors.lastname: Izbicka
authors.forename: C R
authors.initials: CR
authors.lastname: Dunstan
authors.forename: D
authors.initials: D
authors.lastname: Horn
authors.forename: M
authors.initials: M
authors.lastname: Harris
authors.forename: S
authors.initials: S
authors.lastname: Harris
authors.forename: R
authors.initials: R
authors.lastname: Adams
authors.forename: G R
authors.initials: GR
authors.lastname: Mundy
mesh_terms: D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000502:physiology; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000502:physiology; D006133:Growth Substances / Q000235:genetics / Q000502:physiology*; D006367:HeLa Cells; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000502:physiology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000503:physiopathology*; D010012:Osteogenesis; D010982:Platelet-Derived Growth Factor / Q000235:genetics / Q000502:physiology; D012886:Skull / Q000254:growth & development; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D005346:Fibroblast Growth Factors; D007334:Insulin-Like Growth Factor I